Dr. Al-Samkari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street
Boston, MA 02114
Summary
- Hanny Al-Samkari, M.D. is an Associate Professor of Medicine at Harvard Medical School as well as an NIH- and U.S. DOD-funded clinical investigator and classical hematologist at the Massachusetts General Hospital (MGH) Division of Hematology Oncology. He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis and hemolysis, with focuses in HHT, immune thrombocytopenia and other thrombocytopenias, and hereditary hemolytic anemias. He currently serves as PI for many clinical trials in these areas and is an internationally-recognized expert in the clinical development of novel therapeutics for HHT, hemolytic anemias and thrombocytopenias. He is the current Executive Editor of Hematology: The ASH Education Program, an American Society of Hematology peer-reviewed publication, and has published over 130 peer-reviewed manuscripts. His original research has been featured in The New England Journal of Medicine, The Lancet, and Blood, among other top peer-reviewed journals in hematology and medicine.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018
- University of Pennsylvania Health SystemChief Residency, Internal Medicine, 2014 - 2015
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2011 - 2014
- Washington University in St. Louis School of MedicineClass of 2011
Certifications & Licensure
- MA State Medical License 2015 - 2025
- PA State Medical License 2011 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 78 citationsTherapeutic advances in COVID-19.Naoka Murakami, Robert Hayden, Thomas Hills, Hanny Al-Samkari, Jonathan Casey
Nature Reviews. Nephrology. 2023-01-01 - 1 citations2025 update on clinical trials in immune thrombocytopenia.Hanny Al-Samkari
American Journal of Hematology. 2024-11-01 - 8 citationsNovel therapeutics and future directions for refractory immune thrombocytopenia.Hanny Al-Samkari, Ellis J Neufeld
British Journal of Haematology. 2023-10-01
Abstracts/Posters
- Characterization of the Rate, Predictors, and Thrombotic Complications of Thrombocytosis in Iron Deficiency AnemiaHanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
- Comorbidities and Complications in Adults with Pyruvate Kinase DeficiencyHanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK DeficiencyHanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Training Program DirectorsÍ Workshop61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bl...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- Pomalidomide Efficacious in Hereditary Hemorrhagic TelangiectasiaSeptember 24th, 2024
- Clinical Trial Successfully Repurposes Cancer Drug for Hereditary Bleeding DisorderSeptember 18th, 2024
- Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHTAugust 27th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: